Literature DB >> 956814

Time course of nigrostriatal degeneration in parkinson's disease. A detailed study of influential factors in human brain amine analysis.

P Riederer, S Wuketich.   

Abstract

It could be shown that the post mortem analysis of biogenic amines, precursors and metabolites in the human brain are influenced by various parameters. 1. The patient's medical history; long term observations of the course of the disease; age; sex. 2. Terminal illness; duration of terminal illness. 3. Previous treatment with drugs; last drugs. 4. Time interval between last drug treatment and death; time of day and date of last drug consumption. 5. Rapidity of death; time of death; duration of coma. 6. Changes occurring in tissues before death; patients' constitution during terminal illness. 7. Changes in concentration of the biogenic amines, precursors, and metabolites depending on the patient's age. 8. Time between death and necropsy. 9 Dissection of specimen. 10. Period of storage; temperature of storage. 11. Chronbiological rhythm of substances. 12. Methods of assayL 13. Homogeneity of all mentioned parameters in the control group and patient's group. For the first time it could be demonstrated that the time course of nigrostriatal degeneration, independent of the age of the parkinsonian at the beginning of the illness, is linear for the last stage and the denervation progressively increases as the duration of illness progresses.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 956814     DOI: 10.1007/BF01249445

Source DB:  PubMed          Journal:  J Neural Transm            Impact factor:   3.575


  43 in total

1.  Differential extractions for the spectrophotofluorometric measurement of diverse 5-hydroxy- and 5-methoxyindoles.

Authors:  W B QUAY
Journal:  Anal Biochem       Date:  1963-01       Impact factor: 3.365

2.  L-dopa: effect on concentrations of dopamine, norepinephrine, and serotonin in brains of mice.

Authors:  G M Everett; J W Borcherding
Journal:  Science       Date:  1970-05-15       Impact factor: 47.728

3.  The effect of chronic ethanol administration on the levels of catecholamines in different regions of the rat brain.

Authors:  M E Post; A Y Sun
Journal:  Res Commun Chem Pathol Pharmacol       Date:  1973-11

4.  The significance of brain-amine concentrations.

Authors:  J H Dowson
Journal:  Lancet       Date:  1969-09-13       Impact factor: 79.321

5.  The daily rhythm of HVA, VMA, (VA) and 5-HIAA in depression-syndrome.

Authors:  P Riederer; W Birkmayer; E Neumayer; L Ambrozi; W Linauer
Journal:  J Neural Transm       Date:  1974       Impact factor: 3.575

6.  Antiparkinsonian drugs: inhibition of dopamine uptake in the corpus striatum as a possible mechanism of action.

Authors:  J T Coyle; S H Snyder
Journal:  Science       Date:  1969-11-14       Impact factor: 47.728

7.  Regional distribution of amino acids in human brain obtained at autopsy.

Authors:  T L Perry; K Berry; S Hansen; S Diamond; C Mok
Journal:  J Neurochem       Date:  1971-03       Impact factor: 5.372

8.  Relation of sex and aging to monoamine oxidase activity of human brain, plasma, and platelets.

Authors:  D S Robinson; J M Davis; A Nies; C L Ravaris; D Sylwester
Journal:  Arch Gen Psychiatry       Date:  1971-06

9.  Postmortem changes in brain catecholamine enzymes.

Authors:  I B Black; S C Geen
Journal:  Arch Neurol       Date:  1975-01

10.  Biochemical post-mortem findings in depressed patients.

Authors:  W Birkmayer; P Riederer
Journal:  J Neural Transm       Date:  1975       Impact factor: 3.575

View more
  119 in total

1.  GSK-3β dysregulation contributes to parkinson's-like pathophysiology with associated region-specific phosphorylation and accumulation of tau and α-synuclein.

Authors:  J J Credle; J L George; J Wills; V Duka; K Shah; Y-C Lee; O Rodriguez; T Simkins; M Winter; D Moechars; T Steckler; J Goudreau; D I Finkelstein; A Sidhu
Journal:  Cell Death Differ       Date:  2014-11-14       Impact factor: 15.828

2.  The L-type channel antagonist isradipine is neuroprotective in a mouse model of Parkinson's disease.

Authors:  E Ilijic; J N Guzman; D J Surmeier
Journal:  Neurobiol Dis       Date:  2011-04-16       Impact factor: 5.996

Review 3.  Axon degeneration in Parkinson's disease.

Authors:  Robert E Burke; Karen O'Malley
Journal:  Exp Neurol       Date:  2012-01-18       Impact factor: 5.330

Review 4.  Substantia nigra hyperechogenicity is a risk marker of Parkinson's disease: no.

Authors:  Uwe Walter
Journal:  J Neural Transm (Vienna)       Date:  2010-12-29       Impact factor: 3.575

5.  The pharmacodynamic characterization of an antisense oligonucleotide against monoamine oxidase-B (MAO-B) in rat brain striatal tissue.

Authors:  J E Sprague; T J Worst; K Haynes; C R Mosler; D E Nichols; M D Kane
Journal:  Cell Mol Neurobiol       Date:  2001-02       Impact factor: 5.046

Review 6.  Transplantation into the human brain: present status and future possibilities.

Authors:  O Lindvall
Journal:  J Neurol Neurosurg Psychiatry       Date:  1989-06       Impact factor: 10.154

7.  Pargyline reduces/prevents neuroleptic-induced acute dystonia in monkeys.

Authors:  R Heintz; D E Casey
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

Review 8.  Intranasal administration of neurotoxicants in animals: support for the olfactory vector hypothesis of Parkinson's disease.

Authors:  Rui D S Prediger; Aderbal S Aguiar; Filipe C Matheus; Roger Walz; Layal Antoury; Rita Raisman-Vozari; Richard L Doty
Journal:  Neurotox Res       Date:  2011-10-15       Impact factor: 3.911

Review 9.  Involvement of insulin-regulated aminopeptidase in the effects of the renin-angiotensin fragment angiotensin IV: a review.

Authors:  Bart Stragier; Dimitri De Bundel; Sophie Sarre; Ilse Smolders; Georges Vauquelin; Alain Dupont; Yvette Michotte; Patrick Vanderheyden
Journal:  Heart Fail Rev       Date:  2007-11-08       Impact factor: 4.214

10.  CaV1.3-selective L-type calcium channel antagonists as potential new therapeutics for Parkinson's disease.

Authors:  Soosung Kang; Garry Cooper; Sara F Dunne; Brendon Dusel; Chi-Hao Luan; D James Surmeier; Richard B Silverman
Journal:  Nat Commun       Date:  2012       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.